559 related articles for article (PubMed ID: 28561918)
21. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
22. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
[TBL] [Abstract][Full Text] [Related]
23. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma.
Noda S; Iida H; Fujimoto T; Wakasugi Y; Yabuta N; Sudou M; Hira D; Tani M; Andoh A; Morita SY; Terada T
Cancer Chemother Pharmacol; 2021 Aug; 88(2):281-288. PubMed ID: 33928425
[TBL] [Abstract][Full Text] [Related]
24. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting.
Obi S; Sato T; Sato S; Kanda M; Tokudome Y; Kojima Y; Suzuki Y; Hosoda K; Kawai T; Kondo Y; Isomura Y; Ohyama H; Nakagomi K; Ashizawa H; Miura Y; Amano H; Mochizuki H; Omata M
Hepatol Int; 2019 Mar; 13(2):199-204. PubMed ID: 30671808
[TBL] [Abstract][Full Text] [Related]
25. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan.
Shimozato N; Namisaki T; Okano A; Ohana M; Kinoshita D; Kawasaki T; Aihara Y; Nakatani T; Kinoshita H; Ann T; Saito KO; Yoshida M; Yoshiji H
Anticancer Res; 2022 Jan; 42(1):173-183. PubMed ID: 34969723
[TBL] [Abstract][Full Text] [Related]
27. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
28. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.
Hayashi T; Shibata M; Oe S; Miyagawa K; Honma Y; Harada M
PLoS One; 2020; 15(12):e0244370. PubMed ID: 33351844
[TBL] [Abstract][Full Text] [Related]
29. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma.
Yamaoka K; Kodama K; Hiramatsu A; Ando Y; Kosaka Y; Suehiro Y; Fujii Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Imamura M; Takahashi S; Chayama K; Aikata H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1685-1693. PubMed ID: 33326154
[TBL] [Abstract][Full Text] [Related]
30. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib: first global approval.
Scott LJ
Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
[TBL] [Abstract][Full Text] [Related]
32. A phase I pharmacokinetic study of lenvatinib in Chinese patients with unresectable hepatocellular carcinoma.
Bai Y; Hu X; Ren Z; Hisai T; Yusa W; Weng L; Shiba S; Takase T
Future Oncol; 2022 Jul; 18(22):2413-2424. PubMed ID: 35674480
[TBL] [Abstract][Full Text] [Related]
33. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
34. Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma.
Hirooka M; Ochi H; Hiraoka A; Koizumi Y; Matsuura B; Joko K; Michitaka K; Abe M; Hiasa Y
Intern Med; 2019 Mar; 58(6):791-795. PubMed ID: 30333428
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
Glen H
Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
[TBL] [Abstract][Full Text] [Related]
36. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
37. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH
J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer.
Gupta A; Jarzab B; Capdevila J; Shumaker R; Hussein Z
Br J Clin Pharmacol; 2016 Jun; 81(6):1124-33. PubMed ID: 26879594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]